Weight-loss drug craze appears to be curbing US obesity epidemic

For the first time in a decade, obesity in the US is declining, with levels falling to 43.96% in 2023 from 44.1% last year, a significant change.

Researchers suggest that blockbuster medications like Ozempic may be contributing to the decline in obesity levels, particularly in the South, where prescription rates are high.

The analysis, based on millions of health records, indicates that the use of GLP-1 medications like Ozempic is beginning to positively impact America’s obesity epidemic.

Experts underline that effective weight-loss medications can alter the obesity trajectory, yet challenges such as supply shortages and high costs continue to limit access.

Read at www.mercurynews.com